Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17400555 | 1.00 | KDM4E (0.35) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL8465048 | 1.00 | KDM4E (0.35) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| Hydrochloric Acid SCHEMBL25311522 | 0.98 | KDM4E (0.38) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| Hydrochloric Acid SCHEMBL17386571 | 0.98 | KDM4E (0.38) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| Hydrochloric Acid SCHEMBL25311013 | 0.98 | KDM4E (0.38) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL16297547 | 0.93 | KDM4E (0.31) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL24121363 | 0.77 | KDM4E (0.33) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL15187934 | 0.77 | KDM4E (0.36) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL10018110 | 0.77 | KDM4E (0.33) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL15187935 | 0.77 | KDM4E (0.36) | KDM4ENPC1CYP1A2CYP2D6HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195488-A1 | MEDICINE CONTAINING VITAMIN D DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, USED IN COMBINATION WITH IMMUNOMODULATORY SUBSTANCE | TEIJIN PHARMA LIMITED (JP) | 2025-06-19 | — | — | US | disclosed |
| CN-119451681-A | Medicament containing vitamin D derivative or pharmaceutically acceptable salt or solvate thereof for use in combination with immunomodulatory substance | 帝人制药株式会社 | 2025-02-14 | — | — | CN | disclosed |
| EP-4491185-A1 | MEDICINE CONTAINING VITAMIN D DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, USED IN COMBINATION WITH IMMUNOMODULATORY SUBSTANCE | Teijin Pharma Limited (JP) | 2025-01-15 | — | — | EP | disclosed |
| CN-119241414-A | Vitamin D derivatives having cyclic amine in side chain | 帝人制药株式会社 | 2025-01-03 | — | — | CN | disclosed |
| WO-2024024935-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE HAVING ANTINEOPLASTIC EFFECT | 第一三共株式会社 | 2024-02-01 | — | — | WO | disclosed |
| US-20230348376-A1 | VITAMIN D DERIVATIVE HAVING CYCLIC AMINE IN SIDE CHAIN | TEIJIN PHARMA LIMITED (JP) | 2023-11-02 | — | — | US | disclosed |
| WO-2023171736-A1 | MEDICINE CONTAINING VITAMIN D DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, USED IN COMBINATION WITH IMMUNOMODULATORY SUBSTANCE | 帝人ファーマ株式会社 | 2023-09-14 | — | — | WO | disclosed |
| EP-4215519-A1 | VITAMIN D DERIVATIVE HAVING CYCLIC AMINE IN SIDE CHAIN | Teijin Pharma Limited (JP) | 2023-07-26 | — | — | EP | disclosed |
| CN-116075309-A | Vitamin D derivatives having cyclic amine in side chain | 帝人制药株式会社 | 2023-05-05 | — | — | CN | disclosed |
| WO-2022059684-A1 | VITAMIN D DERIVATIVE HAVING CYCLIC AMINE IN SIDE CHAIN | 帝人ファーマ株式会社 | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195488-A1 | MEDICINE CONTAINING VITAMIN D DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, USED IN COMBINATION WITH IMMUNOMODULATORY SUBSTANCE | VDR, CYP24A1, AQP4 | KDM4E 1262/4885NPC1 789/4885CYP1A2 2782/4885 |
| US-20230348376-A1 | VITAMIN D DERIVATIVE HAVING CYCLIC AMINE IN SIDE CHAIN | VDR, CYP2R1, CYP24A1 | KDM4E 1956/4885NPC1 411/4885CYP1A2 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.